Trial Profile
LEO 32731 - A Phase I Drug-Drug Interaction Study With LEO 32731 and Midazolam in Healthy Male Subjects
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 05 May 2017
Price :
$35
*
At a glance
- Drugs Orismilast (Primary) ; Midazolam
- Indications Atopic dermatitis; Psoriasis
- Focus Pharmacokinetics
- Sponsors LEO Pharma
- 16 Aug 2016 Status changed from completed to discontinued.
- 16 Jun 2016 Status changed from recruiting to completed.
- 29 Apr 2016 New trial record